---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-014127"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2022-09-01T23:59:59+00:00"
generated_at: "2026-06-23T17:07:38.301015+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Protalix BioTherapeutics enters fill/finish deal with Chiesi for PRX-102 launch

## Summary
- Agreement with Chiesi for commercial fill/finish services for PRX-102 (Fabry disease candidate).
- Protalix to supply drug substance; Chiesi will provide fill/finish services for global launch.
- Term through Dec 31, 2025, renewable for 7 years by mutual agreement.
- Letter Agreement modifies License Agreements to establish Chiesi as supplier and potential alternate source.
- Agreement supports anticipated launch; no financial terms disclosed.

## SEC filing metadata
- accession: 0001558370-22-014127
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2022-09-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000155837022014127/0001558370-22-014127-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000155837022014127/plx-20220829x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-014127
- JSON: https://secwatch.observer/filing/0001558370-22-014127.json
- Plain text: https://secwatch.observer/filing/0001558370-22-014127.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.